Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag

ConclusionsPharmacokinetic characteristics of selexipag and its metabolite ACT-333679 following administration of one adult tablet of 200  µg selexipag and four paediatric tablets of 50 µg selexipag were comparable.Trial registrationClinicalTrials.gov identifier: NCT02745860.

Source: European Journal of Drug Metabolism and Pharmacokinetics - June 21, 2017 Category: Drugs & Pharmacology Source Type: research